Latest News
Clinical Trials Roundup | 21 Aug 2026
Merck and Moderna’s intismeran autogene meets its primary endpoint in the Phase 3 INTerpath-001 trial in completely resected melanoma, Ultragenyx’s Genglycos receives FDA accelerated approval as the first treatment for glycogen storage disease type Ia, argenx’s...
Latest News
Women-Led Biotech Is Outperforming. Why Is Capital Lagging?
A new therapeutic can take a decade. Often hundreds of millions of dollars. Regulators checking the work at every stage along the way. So when a category of founders consistently delivers better returns on less capital, you'd expect investment patterns to reflect...
CSRD Reporting: What Has Changed for European Biotech
The European Union has rewritten its sustainability disclosure rules. The consequences for the life sciences sector are substantial. CSRD reporting was once expected to capture tens of thousands of companies across the bloc. It now applies to a far smaller group of...
Microalgae Biomaterials: Where the Carbon Math Holds, and Where it Fails
A research team at the University of Colorado Boulder took a marine dinoflagellate called Pyrocystis lunula, mixed it into 4 wt% sodium alginate, crosslinked the gel ionically in calcium chloride, and extruded it through a Cellink BIO X bioprinter into printed grids...
NHS Golden Jubilee First Scottish Hospital to Adopt Steriwave
NHS Golden Jubilee Becomes First Scottish Hospital to Adopt Light-Activated Infection Prevention Technology to Prevent Surgical Site Infections GLASGOW — Scotland’s flagship orthopaedic hospital, NHS Golden Jubilee, has become the first in the country to adopt an...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Why AI May Increase Cognitive Burden Before Reducing It
It seems that artificial intelligence is being proposed as an answer to what could be considered as one of the most serious problems facing the life sciences sector – the problem of information overload. There has never been as much data, documentation, literature,...
The Seduction of Ease: Burnout, AI, and Human Leadership in Life Sciences
Life sciences exist to do something extraordinary. Their applied solutions seek to understand biology and improve health and the quality of life for humans, animals, and plants. That is not a small mission; at its core, it is deeply human. It is the kind of mission...
CagriSema: Strong Obesity Data, but can it Beat Tirzepatide?
CagriSema, the once-weekly obesity therapy from Novo Nordisk, has spent more than a year as the most closely watched candidate in metabolic medicine. The combination of cagrilintide and semaglutide promised weight loss beyond what either molecule could achieve alone....
Improving Oncolytic Virus Development for Cancer Immunotherapy Research
Oncolytic virus development is gaining increasing attention in cancer immunotherapy research because of its ability to combine direct tumor cell killing with immune activation. Unlike conventional therapeutic strategies that focus on one pathway or one target,...
Will Artificial Intelligence Replace Medical Science Liaisons?
What Global Surveys of Medical Affairs Professionals Reveal Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, prompting many Medical Affairs professionals to ask whether some roles may eventually become obsolete. Headlines regularly...
GLP-1 Uptake by Country: Where Ozempic and Mounjaro are Booming in 2026
The global market for glucagon-like peptide-1 (GLP-1) receptor agonists has entered a new phase. What began as a breakthrough in type 2 diabetes management has become one of the defining pharmaceutical stories of the decade. In 2025, the GLP-1 receptor agonist market...
AI’s Next Leap in Biopharma: From Acceleration to Intelligence in Partnership
Artificial intelligence has already changed the rhythm of discovery in biopharma. Algorithms can screen millions of molecules, identify trial candidates, and forecast supply chains with extraordinary speed. Yet speed is not the same as progress. The next chapter of AI...
Weekly News Roundup | 15 June 2026
Life science news 15 June 2026: GSK's $10.6 billion Nuvalent acquisition headlines a blockbuster M&A week, the MHRA approves the UK's first oral weight-loss semaglutide tablet, and the FDA clears a new adjuvant combination for kidney cancer in a landmark week for...
What GLP-1 Patients Don’t Know About Muscle Loss and Why It Matters
GLP-1 receptor agonists are transforming obesity treatment. But the clinical conversation about lean muscle preservation is lagging behind the prescribing rate, and that gap has real consequences for patients, says Omar el-Gohary. There is a version of the GLP-1...
Why Europe’s Precision Oncology Trials Keep Stalling
Precision medicine works when the right biomarker test reaches the right patient in time. In Europe, the regulatory plumbing is making that harder than it should be. At the 16th Clinical Biomarkers & CDx Summit in London in March 2026, I discussed lessons from MDx...
Complement Inhibitor Setback: Sanofi Halts CIDP Study
Sanofi has halted a late-stage trial of its experimental complement inhibitor riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), a setback that analysts say could create volatility across the wider complement inhibitor field. The company said in...
Clinical Trials Roundup | 12 June 2026
Survodutide delivers dual Phase 3 success in obesity and metabolic liver disease at ADA 2026, secukinumab becomes the first targeted biologic to demonstrate sustained remission in polymyalgia rheumatica, dapirolizumab pegol meets its Phase 3 primary endpoint in...
Why AI May Increase Cognitive Burden Before Reducing It
It seems that artificial intelligence is being proposed as an answer to what could be considered as one of the most serious problems facing the life sciences sector – the problem of information overload. There has never been as much data, documentation, literature,...
The Seduction of Ease: Burnout, AI, and Human Leadership in Life Sciences
Life sciences exist to do something extraordinary. Their applied solutions seek to understand biology and improve health and the quality of life for humans, animals, and plants. That is not a small mission; at its core, it is deeply human. It is the kind of mission...
CagriSema: Strong Obesity Data, but can it Beat Tirzepatide?
CagriSema, the once-weekly obesity therapy from Novo Nordisk, has spent more than a year as the most closely watched candidate in metabolic medicine. The combination of cagrilintide and semaglutide promised weight loss beyond what either molecule could achieve alone....
Improving Oncolytic Virus Development for Cancer Immunotherapy Research
Oncolytic virus development is gaining increasing attention in cancer immunotherapy research because of its ability to combine direct tumor cell killing with immune activation. Unlike conventional therapeutic strategies that focus on one pathway or one target,...
Will Artificial Intelligence Replace Medical Science Liaisons?
What Global Surveys of Medical Affairs Professionals Reveal Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, prompting many Medical Affairs professionals to ask whether some roles may eventually become obsolete. Headlines regularly...
GLP-1 Uptake by Country: Where Ozempic and Mounjaro are Booming in 2026
The global market for glucagon-like peptide-1 (GLP-1) receptor agonists has entered a new phase. What began as a breakthrough in type 2 diabetes management has become one of the defining pharmaceutical stories of the decade. In 2025, the GLP-1 receptor agonist market...
AI’s Next Leap in Biopharma: From Acceleration to Intelligence in Partnership
Artificial intelligence has already changed the rhythm of discovery in biopharma. Algorithms can screen millions of molecules, identify trial candidates, and forecast supply chains with extraordinary speed. Yet speed is not the same as progress. The next chapter of AI...
Weekly News Roundup | 15 June 2026
Life science news 15 June 2026: GSK's $10.6 billion Nuvalent acquisition headlines a blockbuster M&A week, the MHRA approves the UK's first oral weight-loss semaglutide tablet, and the FDA clears a new adjuvant combination for kidney cancer in a landmark week for...
What GLP-1 Patients Don’t Know About Muscle Loss and Why It Matters
GLP-1 receptor agonists are transforming obesity treatment. But the clinical conversation about lean muscle preservation is lagging behind the prescribing rate, and that gap has real consequences for patients, says Omar el-Gohary. There is a version of the GLP-1...
Why Europe’s Precision Oncology Trials Keep Stalling
Precision medicine works when the right biomarker test reaches the right patient in time. In Europe, the regulatory plumbing is making that harder than it should be. At the 16th Clinical Biomarkers & CDx Summit in London in March 2026, I discussed lessons from MDx...
Complement Inhibitor Setback: Sanofi Halts CIDP Study
Sanofi has halted a late-stage trial of its experimental complement inhibitor riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), a setback that analysts say could create volatility across the wider complement inhibitor field. The company said in...
Clinical Trials Roundup | 12 June 2026
Survodutide delivers dual Phase 3 success in obesity and metabolic liver disease at ADA 2026, secukinumab becomes the first targeted biologic to demonstrate sustained remission in polymyalgia rheumatica, dapirolizumab pegol meets its Phase 3 primary endpoint in...
Featured Articles
Further News
Foundayo vs Rybelsus: The Oral GLP-1 Guide for 2026
The oral GLP-1 market has changed faster in the past six months than in the previous six years. Where once Rybelsus stood alone as the only GLP-1 pill available, patients and clinicians must now navigate three distinct oral products, each with a different molecule, a...
The Case for Agility: Why Biopharma Must Embrace Adaptive Trial Designs
For decades, the landscape of clinical research was dominated by fixed, traditional trial designs. In these legacy studies, the primary objective was often maintaining a strict, unchanging protocol from inception to conclusion. But the landscape of modern medicine has...
GSK’s $10.6 Billion Nuvalent Deal: Reshaping the Lung Cancer Drug Race
Two FDA decision dates, 18 September and 27 November, are now the most important dates on GSK's calendar. On 9 June 2026, the British pharmaceutical giant announced it had agreed to acquire Cambridge, Massachusetts-based Nuvalent for $10.6 billion in cash, securing...
FDA Drug Approval Decisions: June and July 2026
The summer months at the United States Food and Drug Administration are typically among the busiest on the regulatory calendar, and 2026 is proving no exception. With a succession of high-profile FDA drug approval decisions concentrated in June and July 2026, the...
Importance of Targeted Radiotherapeutics in Treating CNS Cancers
Radiation therapy is one of the important tools in the fight against cancer. About 50% of all cancer patients receive radiation therapy. Few modalities have had the same lasting impact across such a broad range of tumor types. In central nervous system (CNS) oncology,...
How Compassion Protects Healthcare Workers from Empathy Fatigue
Working professionals know the feeling of being worn out at the end of a long, demanding day; however, burnout is considered a more intense, full-body breakdown resulting from longer-term exhaustion. Herbert Freudenberger, Ph.D., who coined the term burnout, defined...
Daraxonrasib Doubles Survival in Pancreatic Cancer at ASCO
When Brian Wolpin, Professor of Medicine at Harvard Medical School and Director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, advanced to the next slide during the plenary session at the 2026 ASCO (American Society of...
Clinical Insight: The Future of Sensory-Based Therapeutics in Healthcare
The role of sensory systems in human health has long been established within biological and neuroscientific research. Olfactory, auditory, and tactile pathways are deeply integrated into the body’s regulatory networks, influencing emotional processing, cognitive...
Dementia Relief Through Silence and Brain Wave Modulation
In silence, the brain regenerates, growing new neurons in the hippocampus which is the cerebral center of memory, spatial navigation and emotional regulation (Kriste, Nicola, Kronenberg, Walker, Liu, & Kempermann, 2015). Silence has also been shown to be relaxing...
The Silent Epidemic: Workplace Bullying in Healthcare
Workplace Bullying in Healthcare and the Leadership Response Healthcare is one of the most demanding professional environments on earth. Clinicians make high-stakes decisions under pressure, routinely absorb the grief and trauma of others, and operate within systems...
Weekly News Roundup | 8 June 2026
Life science news 8 June 2026: ASCO delivers landmark oncology data, GSK achieves hepatitis B functional cure breakthrough, and Servier secures a $2.65 billion rare disease deal in a milestone week for the industry. Revolution Medicines presented full Phase 3 data for...
The Scaling Crisis in Cell and Gene Therapy
There are FDA-approved therapies on the market today that can permanently resolve a disease in a single administration, for a price of one to three million dollars. The reimbursement system responsible for covering that cost was built around medications that people...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.